130569-31-2

Usage

Uses

Used in Research Applications:
5,6-Dichloro-2,3-dihydro-1H-inden-1-ol is used as a research chemical for studying its properties and potential applications in various scientific fields. Its unique structure and composition make it a valuable compound for exploring new chemical reactions and processes.
Used in Industrial Applications:
In industrial settings, 5,6-Dichloro-2,3-dihydro-1H-inden-1-ol is used as an intermediate or a component in the synthesis of other chemicals or materials. Its specific role in these applications depends on the requirements of the industry and the desired end product.
Used in Environmental Studies:
5,6-Dichloro-2,3-dihydro-1H-inden-1-ol is used in environmental studies to understand the impact of organochlorine compounds on ecosystems and human health. Research in this area helps to develop strategies for mitigating the potential risks associated with these compounds.
Used in Toxicological Studies:
Due to its chlorine content, 5,6-Dichloro-2,3-dihydro-1H-inden-1-ol is used in toxicological studies to investigate its potential toxicity and effects on living organisms. This information is crucial for assessing the safety of its use in various applications and for developing guidelines for its handling and disposal.

Upstream product

• 68755-31-7 5,6-dichloro-2,3-dihydro-1H-inden-1-one 
• 90273-67-9 3-(3,4-dichlorophenyl)propionic acid chloride 
• 25173-68-6 3(3,4-dichlorophenyl)propanoic acid 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the Na+/H+ Exchanger Type 3 (NHE3)

The design, synthesis, and structure-activity relationship of 1-phenoxy-2-aminoindanes as inhibitors of the Na+/H+ exchanger type 3 (NHE3) are described based on a hit from high-throughput screening (HTS). The chemical optimization resulted in the discovery of potent, selective, and orally bioavailable NHE3 inhibitors with 13d as best compound, showing high in vitro permeability and lacking CYP2D6 inhibition as main optimization parameters. Aligning 1-phenoxy-2-aminoindanes onto the X-ray structure of 13d then provided 3D-QSAR models for NHE3 inhibition capturing guidelines for optimization. These models showed good correlation coefficients and allowed for activity estimation. In silico ADMET models for Caco-2 permeability and CYP2D6 inhibition were also successfully applied for this series. Moreover, docking into the CYP2D6 X-ray structure provided a reliable alignment for 3D-QSAR models. Finally 13d, renamed as SAR197, was characterized in vitro and by in vivo pharmacokinetic (PK) and pharmacological studies to unveil its potential for reduction of obstructive sleep apneas.

Indanes useful as analgesics

Novel indanes in all possible stereoisomer forms of the formula STR1 wherein the substrates are as defined in the application and their non-toxic, pharmaceutically acceptable acid addition salts and their hydrates are disclosed as having central analgesic